CUDC-101 - HDAC/EGFR/HER2 Inhibitor. CAS# 1012054-59-9 60129 Differential sensitivity of hypoxia inducible

Differential sensitivity of hypoxia inducible factor hydroxylation sites to hypoxia and hydroxylase inhibitors

another Wnt signaling inhibitor) produced robust cardiac differentiation of hESCs/iPSCs in a xeno-free

5-a]pyrimidin-7-yl]phenyl]-N-methylacetamide

and serves as an excellent chemical probe for investigating DOT1L and further development of DOT1L inhibitors for cancer therapy

CUDC-101 - HDAC/EGFR/HER2 Inhibitor. CAS# 1012054-59-9 60129 Differential sensitivity of hypoxia inducibleCUDC 101, CAS No. 1012054 59 9, is a potent multi target inhibitor targeting HDAC, EGFR and HER2 with IC50 of 4. 4 nM, 2. 4 nM, and 15. 7 nM, respectively. It is specific for class I and class II HDACs, not for class III Sir type HDACs, and has > 50 fold selectivity against other protein kinases. CUDC 101 displays broad antiproliferative activity in many human cancer cell types with IC50 of 0. 04 0. 80 M, exhibiting a higher potency than erlotinib,